← Back to guidelines
Hematology7 papers

Primary ITP (immune thrombocytopenia)

Last edited: 4/10/2026

Overview

Primary immune thrombocytopenia (ITP), formerly known as immune thrombocytopenic purpura, is a disease for which clinical and therapeutic management has historically been controversial 3. Guidelines from the American Society of Hematology (ASH) aim to support patients and clinicians in decisions about ITP management in adults and children 2.

Diagnosis

  • Guidelines for the diagnosis of primary immune thrombocytopenia in children have been updated by the Spanish Society of Paediatric Haematology and Oncology 3.
  • Specific diagnostic criteria or recommended tests are not detailed in the provided abstracts.
  • Management

  • The American Society of Hematology (ASH) guidelines cover management of ITP in adults and children with newly diagnosed, persistent, and chronic disease refractory to first-line therapy, specifically for those with non-life-threatening bleeding 2.
  • Management approaches include observation, corticosteroids, IV immunoglobulin, anti-D immunoglobulin, rituximab, splenectomy, and thrombopoietin receptor agonists 2.
  • The Spanish guidelines for pediatric ITP aim to reduce clinical variability in therapeutic procedures to achieve optimal clinical results with minimal adverse events and good quality of life 3.
  • Special Populations

  • Pediatrics: Both ASH and Spanish guidelines address ITP management in children 23. The Spanish guidelines are specifically focused on primary immune thrombocytopenia in children 3.
  • Adults: ASH guidelines cover ITP management in adults 2.
  • References

    1 Zheng XL, Al-Housni Z, Cataland SR, Coppo P, Geldziler B, Germini F et al.. 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura. Journal of thrombosis and haemostasis : JTH 2025. link 2 Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N et al.. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood advances 2019. link 3 Monteagudo E, Astigarraga I, Cervera Á, Dasí MA, Sastre A, Berrueco R et al.. [Protocol for the study and treatment of primary immune thrombocytopenia: PTI-2018]. Anales de pediatria 2019. link

    Original source

    1. [1]
      2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura.Zheng XL, Al-Housni Z, Cataland SR, Coppo P, Geldziler B, Germini F et al. Journal of thrombosis and haemostasis : JTH (2025)
    2. [2]
      American Society of Hematology 2019 guidelines for immune thrombocytopenia.Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N et al. Blood advances (2019)
    3. [3]
      [Protocol for the study and treatment of primary immune thrombocytopenia: PTI-2018].Monteagudo E, Astigarraga I, Cervera Á, Dasí MA, Sastre A, Berrueco R et al. Anales de pediatria (2019)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG